Biologics: Targets and Therapy

Dovepress
Taylor & Francis Group

Open Access Full Text Article

REVIEW

Advancing Monoclonal Antibody Manufacturing: Process Optimization, Cost Reduction Strategies, and Emerging Technologies

Ranjit Ranbhor

Pergament & Cepeda LLC, Florham Park, NJ, 07932, USA

Correspondence: Ranjit Ranbhor, Pergament & Cepeda LLC, Florham Park, NJ, 07932, USA, Tel +1 973 967 0490, Email ranjitranbhor@gmail.com

Purpose: This review examines recent advances in monoclonal antibody (mAb) manufacturing, focusing on process optimization, cost reduction strategies, and emerging technologies. The analysis addresses critical challenges in current manufacturing processes while evaluating innovative solutions to improve production efficiency and economic viability.

Methods: We conducted a comprehensive analysis of recent literature on mAb manufacturing, examining traditional batch processing, continuous processing, and hybrid systems. The review evaluates cost optimization strategies, including media development and process integration, while assessing the impact of emerging technologies, such as machine learning and advanced analytics, on manufacturing efficiency.

Results: Recent studies demonstrate that continuous processing can achieve up to 35% cost savings compared to traditional batch processing to meet an annual production demand of 100–500 kg, though this gain diminishes at larger scales. Hybrid facilities show accelerated break-even points, reaching profitability 2–2.5 years earlier than traditional facilities. Advanced media optimization strategies, incorporating novel tripeptide delivery methods, have demonstrated up to 35% improvement in mAb titers. Integration of machine learning and advanced analytics has significantly enhanced process control and optimization capabilities.

Conclusion: The evolution of mAb manufacturing technologies offers promising pathways for improving production efficiency and reducing costs. Scale-dependent considerations remain crucial in selecting optimal manufacturing strategies, while emerging technologies present new opportunities for process optimization. Future developments in continuous processing, advanced analytics, and cell line engineering will be essential in meeting growing global demand while ensuring economic viability and accessibility of mAb therapeutics.

Plain Language Summary: Though monoclonal antibodies (mAbs) have changed therapy for cancer and autoimmune illnesses, they struggle with accessibility because of manufacturing complexity and high cost.

Our analysis shows: continuous processing provides up to 35% cost reductions for 100–500kg annual production in comparison to batch techniques; hybrid facilities reach break-even 2–5 years sooner than conventional setups; and innovative tripeptide delivery systems increase mAb titers by 35%.

The combination of machine learning and sophisticated analytics is most encouraging since it allows real-time monitoring and parameter modification to enhance product uniformity and resource use.

These developments could increase patient access by opening doors to more reasonably priced mAb therapies, and they could also enhance manufacturing economic conditions for manufacturers. Although scaling issues remain, the combination of process innovation and computer technologies points to a revolutionary future for mAb production.

Keywords: biosimilar, biomanufacturing, process optimization, continuous processing, cost reduction, machine learning, advanced analytics

Received: 6 January 2025
Accepted: 5 April 2025
Published: 9 April 2025

Introduction

Monoclonal antibodies (mAbs) have emerged as a cornerstone of modern therapeutic interventions, revolutionizing the treatment of various diseases, such as cancer, autoimmune disorders, and inflammatory conditions.[1–3] Despite their clinical success, mAb manufacturing presents various challenges that impact their accessibility and commercial viability. Recent studies indicate that process development and manufacturing costs constitute 13%–17% of the total research and development (R&D) budget from the pre-clinical to approval stages, with material preparation costs reaching approximately 60–70 million USD for successful market entries.[4]

The manufacturing of mAbs faces several critical challenges that demand immediate attention. Current production processes often suffer from inefficiencies in cell line development, media optimization, and downstream processing.[5,6] Traditional batch manufacturing approaches, though well-established, frequently result in suboptimal resource utilization and extended production cycles. Furthermore, heavy reliance on expensive components, such as protein A in purification steps, contributes significantly to the overall cost of goods (COGs), with recent research demonstrating the potential of 23% cost reduction through alternative purification platforms.[7]

The economic considerations in mAb manufacturing are particularly pressing given the increasing demand for these therapeutics. Production costs directly influence drug pricing and accessibility, making cost optimization a crucial factor in the industry's sustainable growth. Transitioning from traditional stainless steel facilities to single-use continuous facilities can offer up to 35% cost savings in meeting annual production demand of 100–500 kg, though this gain diminishes at higher scales.[8]

Given these challenges, there is a critical need to address high production costs and process inefficiencies in mAb manufacturing. Current production methods often require substantial capital investment, face scalability challenges, and struggle with batch-to-batch consistency. These inefficiencies not only impact production economics but also affect product quality[9] and time-to-market. The industry requires innovative solutions to optimize production processes while maintaining product quality and regulatory compliance.

Three main production techniques—batch, fed-batch, and continuous (perfusion) processing—present different advantages and constraints that greatly affect process economics and product quality when looking at manufacturing options for biopharmaceuticals (Figure 1). Although logistically straightforward, batch processing causes nutrition depletion and waste accumulation, which compromises product quality and causes early cell death.[10] By means of strategic feeding schedules, fed-batch processing solves these constraints; nonetheless, it creates process complexity and scale-up difficulties.[11] With cost savings of roughly 35% for annual production demand between 100 and 500 kg, continuous processing achieves the highest cell densities ($50–100\times10^6$ cells/mL vs $15–25\times10^6$ cells/mL for fed-batch) and volumetric productivity (0.5–2.0 g/L/day vs 0.2–0.5 g/L/day for fed-batch) as shown in Table 1.

The advantages of certain fermentation techniques in biopharmaceutical manufacturing are rather well supported by recent studies. A particularly successful technique for improving product yields in recombinant proteins manufacture has been Fed-batch fermentation. Mendes et al[12] revealed that fed-batch bioreactor production of recombinant BCG showed enhanced specific growth rates after day 4 in pH 7.4-controlled cultures, hence lowering the cultivation time relative to simple batch processing. Their research also showed that fed-batch samples showed substantial recovery of viable cell counts post-lyophilization, implying that extra nutrient supplementation during fermentation may protect cells during downstream processing. Continuous fermentation techniques have many interesting benefits for maximizing output. Continuous fermentation of penicillium brevicompactum achieved notably better productivity (0.025 g/L/h) of mycophenolic acid compared to fed-batch (0.007 g/L/h) and batch fermentation (0.006 g/L/h), Anand and Srivastava[13] found in their comparative investigation. With an ideal dilution rate of 0.015 h-1, their studies found that continuous culture essentially reduced substrate inhibitory effects and preserved the organism in a stronger adaptive condition. Though they remain vulnerable to contamination difficulties, Yi[14] pointed out that continuous fermentation systems run free through constant or occasional injection of fresh nutrient medium without any limits. These results imply that, with suitable application of continuous processing technologies, similar efficiency benefits could be obtained in monoclonal antibody production.

This review aims to comprehensively evaluate current manufacturing approaches, analyze cost reduction strategies, and assess emerging technologies in mAb production. Specifically, we examine the evolution from traditional batch processing to continuous and hybrid manufacturing systems, evaluate various cost optimization strategies, including media development and process integration, and explore the potential of emerging technologies, such as machine



Figure 1 Key differences between batch, fed-batch, and continuous fermentation processes.

learning and advanced analytics in process optimization. Through this analysis, we provide evidence-based recommendations for future developments in mAb manufacturing.

The advancements in mAb manufacturing technologies and strategies are crucial to meet the growing global demand of these therapeutics while ensuring their economic viability.[15] By addressing current challenges and leveraging emerging technologies, the industry can work toward more efficient, cost-effective, and sustainable production processes. This review synthesizes recent developments and provides a framework for future innovations in mAb manufacturing optimization.

Manufacturing Approaches and Process Design in mAb Production

The manufacturing of mAbs has evolved significantly over recent decades, with various approaches emerging to address production challenges and economic constraints. This section examines three primary manufacturing strategies, namely,

Table 1 Process Performance Comparison

Parameter	Batch	Fed-Batch	Continuous (Perfusion)
Typical duration	7–10 days	14–21 days	30–90+ days
Maximum cell density	2–5×10^6 cells/mL	15–25×10^6 cells/mL	50–100×10^6 cells/mL
Volumetric productivity	0.05–0.1 g/L/day	0.2–0.5 g/L/day	0.5–2.0 g/L/day
Final titer	0.5–1 g/L	3–10 g/L	20–30 g/L (cumulative)
Nutrient limitations	Severe	Moderate	Minimal
Waste accumulation	High	Moderate	Low
Equipment utilization	~30%	~50%	~80%
Process complexity	Low	Medium	High
Scale-up challenges	Minimal	Moderate	Significant

https://doi.org/10.2147/BTT.S515078

batch processing, continuous processing, and hybrid systems, analyzing their relative merits and limitations in modern biopharmaceutical production.

Batch processing remains the traditional backbone of mAb manufacturing, characterized by discrete production cycles where a single batch is processed from start to finish before initiating the next batch. This approach offers several advantages, including well-established regulatory compliance pathways and simplified process validation. However, batch processing faces limitations in terms of equipment utilization, facility footprint requirements, and operational efficiency. Cost considerations for batch processing are particularly significant, with studies indicating higher capital investment requirements and potentially lower volumetric productivity than in alternative approaches.[8]

Continuous processing has emerged as a promising alternative, offering significant advantages through end-to-end bioprocessing. Recent research demonstrates that single-use continuous facilities can achieve approximately 35% cost savings compared to traditional stainless steel batch facilities in meeting the annual production demand of 100–500 kg.[8] These economic benefits are particularly pronounced at specific production scales and diminish to approximately ±10% at higher production volumes (1–3 tons) due to the requirement for multiple parallel continuous trains. Implementation challenges include the requirement of robust process control strategies, real-time monitoring capabilities, and addressing concerns about system stability over extended production runs.[16]

Hybrid systems represent a middle-ground approach, combining disposable and stainless steel equipment to leverage the advantages of both technologies. Studies have shown that hybrid facilities can achieve faster break-even points, typically 2–2.5 years earlier than the traditional stainless steel facilities.[17] The flexibility benefits of hybrid systems are particularly noteworthy, allowing manufacturers to optimize their process based on scale, product requirements, and economic considerations. Cost analysis reveals that a 3×2000 L bioreactor configuration with pooled harvesting often proves most cost-effective in hybrid setups among all the setups. A comparative analysis of key performance metrics across these manufacturing approaches is presented in Table 2.

Growing use of continuous processing for monoclonal antibody manufacture clearly marks a paradigm change in manufacturing techniques. David et al[18] conducted a thorough side-by-side comparability research where continuous downstream processing showed equivalent product quality attributes to conventional batch processing with notable benefits. By 6-fold and chromatography resin use by 2.4-fold compared to fed-batch platforms, the study found that continuous manufacturing drastically cut buffer consumption. Moreover, they showed that changing from batch to continuous processing had no appreciable effect on final drug substance properties like stability profiles, process-related contaminants, and product quality parameters. This highlights the possibility of using constant manufacturing at any level of the product life. Botelho Ferreira et al[19] also showed another creative way by effectively using the current fed-batch infrastructure for continuous processing, thereby implementing a hybrid manufacturing technique. Their approach performed perfusion operation in a 200-L single-use bioreactor using downstream processes intended for future continuous manufacturing platform compatibility. By allowing 2.1 kg of monoclonal antibody to be produced in two GMP runs, this method showed that "existing fed-batch infrastructure can be adapted to continuous manufacturing without significant additional investments". Cha et al[20] also compared fed-batch and perfusion culture techniques for

Table 2 Key Performance Metrics Across Manufacturing Approaches

Parameter	Batch Processing	Continuous Processing	Hybrid Systems
Cost Savings (100–500 kg/year)	Baseline	Up to 35%	20–25%
Break-even Timeline	Baseline	Variable	2–2.5 years faster
Capital Investment	High	Medium	Medium-High
Operational Flexibility	Low	Medium	High
Scale-up Complexity	Low	High	Medium
Regulatory Compliance	Well-established	Emerging	Intermediate

commercial-scale production, determining that perfusion cultures attained 1.6-fold higher peak viable cell density with longer culture duration, thus generating a total product amount increase of over 450% while improving purification yield. Their economic study indicated that perfusion mode might lower the cost of goods while preserving product quality, therefore demonstrating its feasibility as a practical method of commercial antibody manufacturing.

The choice of these manufacturing approaches depends on various factors, such as production scale, facility constraints, and economic objectives. While continuous processing shows promise of cost reduction and improved efficiency, batch processing maintains advantages in regulatory compliance and operational simplicity. Hybrid systems offer a balanced approach, particularly suitable for facilities requiring flexibility in production capacity and product types.

Recent advancements in process analytical technology (PAT) and real-time monitoring systems have enhanced the viability of all the three approaches, though each continues to present unique implementation and optimization challenges. Understanding these trade-offs is crucial for manufacturers in selecting the most appropriate production strategy for their specific needs and constraints. Scale-dependent considerations play a crucial role in manufacturing strategy selection, as detailed in Table 3.

This analysis of manufacturing approaches provides a foundation for understanding the complex decisions that mAb producers face and the ongoing evolution of production strategies in the biopharmaceutical industry.

Cost Optimization Strategies in mAb Manufacturing

The optimization of production costs remains a critical challenge in mAb manufacturing, requiring a multifaceted approach encompassing media development, process integration, and strategic technology selection.[21] Recent advances in these areas have demonstrated significant potential in cost reduction while maintaining or improving product quality.

Media optimization represents a fundamental strategy for cost reduction, with particular emphasis on chemically defined feed media development. Kishishita et al[22] identified key amino acids (serine, cysteine, and tyrosine) that significantly improved mAb production when added to feed media. The development of novel tripeptide delivery methods has shown promise in improving amino acid solubility and delivery, resulting in up to 35% improvement in mAb titers. Furthermore, strategic supplementation approaches have demonstrated success in reducing lactate accumulation and enhancing cell viability through optimized media composition.

Process integration has emerged as a crucial factor in cost optimization, focusing on the harmonization of upstream and downstream operations. Studies indicate that improved integration between these processes can significantly reduce overall manufacturing costs while enhancing product quality. Equipment utilization plays a vital role in this context, with research showing that optimized scheduling and facility design can improve productivity by 20%–30%.[8] Facility design[23,24] considerations must balance multiple factors, including:

- Clean room requirements
- Material flow optimization
- Equipment placement efficiency
- Utility systems integration

Table 3 Economic Comparison Across Manufacturing Scales

Annual Production	Most Economical Approach	Key Economic Drivers
<100 kg	Fed-batch	Lower capital investment, simplified operations
100–500 kg	Continuous	~35% lower CoGS, reduced facility footprint
500–1000 kg	Hybrid approaches	Balancing fixed and variable costs
>1000 kg	Multiple strategies viable	Dependent on portfolio diversity and facility flexibility

https://doi.org/10.2147/BTT.S515078

Technology selection represents the third pillar of cost optimization, with scale-dependent considerations playing a crucial role in decision-making. Research demonstrates that single-use systems offer significant advantages at smaller scales (100–500 kg annual production), whereas traditional stainless steel systems may be more economical at larger scales. The cost–benefit analysis must include multiple factors:

- Initial capital investment
- Operational costs
- Maintenance requirements
- Production flexibility
- Environmental impact

Recent studies have shown that hybrid approaches, combining both single-use and traditional systems, can offer optimal solutions for many manufacturers. According to Sinclair and Monge,[17] hybrid facilities demonstrate faster break-even points, typically achieving profitability 2–2.5 years earlier than traditional facilities. This advantage stems from lower upfront capital costs and improved cash flow profiles, though careful consideration must be given to increased consumable costs.

The successful implementation of these optimization strategies requires careful consideration of facility-specific factors and product requirements. The integration of advanced PAT and real-time monitoring systems has proven essential in maximizing the benefits of these approaches. Furthermore, the adoption of quality by design (QbD) principles has demonstrated potential in reducing costs while maintaining product quality and regulatory compliance.

This comprehensive approach of cost optimization, incorporating media development, process integration, and technology selection, provides a framework for manufacturers to achieve significant cost reductions while maintaining product quality and manufacturing efficiency. The selection and implementation of these strategies must be tailored to specific facility requirements and production objectives to maximize their effectiveness. Figure 2 provides a comprehensive overview of the interconnected components in modern mAb manufacturing, from traditional approaches to emerging technologies.

Emerging Technologies and Future Directions in mAb Manufacturing

The landscape of mAb manufacturing is rapidly evolving with the integration of advanced technologies and novel approaches. Recent developments in machine learning, advanced analytics, and production platforms are revolutionizing traditional manufacturing processes, offering unprecedented opportunities for optimization and efficiency improvements.

Machine learning applications have emerged as powerful tools in mAb manufacturing.[25,26] Machine learning approaches for protein expression optimization have shown particular promise as highlighted by Nikolados and Oyarzún and others.[27,28] Their research demonstrates that deep learning models can accurately predict protein expression levels directly from nucleotide sequences, enabling more efficient sequence optimization for improved yields. Process optimization through machine learning has enabled real-time adjustment of critical process parameters, whereas



Figure 2 Evolution of modern mAb manufacturing technologies.

advanced monitoring systems utilize artificial intelligence to detect and respond to process deviations more rapidly than traditional methods.[29,30]

Artificial neural networks (ANNs) have been effectively used in upstream processing to estimate the solubility of recombinant proteins in *Escherichia coli* fed-batch cultivations and product titer. To estimate cell biomass and protein concentration with an accuracy of ±4% and ±12%, respectively, one prominent example used a radial basis function ANN with partial least squares regression and multiwavelength fluorescence data.[31]

An ANN-mechanistic hybrid model was applied for root cause analysis of process deviations in ion exchange chromatography, thereby enabling real-time monitoring by ascertaining the reason and extent of deviations in milliseconds.[32] Using feed stream parameters to estimate suitable filter sizing, another application used ANNs to predict depth filter loading capacity for clarity of monoclonal antibodies in commercial manufacture.[33]

Emerging artificial intelligence method reinforcement learning has shown promise in control optimization, such as in a liquid–liquid extraction process where it attained 32% higher recovery and 23% smaller operational deviations compared to conventional controls.[34] Three times faster than traditional trial-and-error approaches, reinforcement learning was also applied to maximize parameters in cation-exchange chromatography.[35]

Advanced analytics have become increasingly crucial in modern mAb manufacturing, with PAT leading the way in real-time process monitoring and control.[36] This technology enables continuous assessment of critical quality attributes, allowing for immediate process adjustments to maintain optimal conditions. QbD principles have been integrated with advanced analytics to create robust manufacturing processes that ensure consistent product quality. As demonstrated by Broly et al,[37] combining cost analysis with QbD can optimize manufacturing processes while maintaining product quality standards. Data-driven decision-making has become central to process optimization, with integrated systems collecting and analyzing vast amounts of process data to inform operational improvements. Different manufacturing approaches also significantly impact product quality attributes, as summarized in Table 4.

Novel production platforms represent the third frontier in emerging technologies. Recent advances in cell line development, as detailed by Majumdar et al,[38] have focused on:

- Improved promoter and enhancer elements
- Chromatin-modifying elements for consistent expression
- Codon optimization strategies
- Signal sequence optimization

Vector engineering has seen significant progress, with new approaches to improve expression stability and product quality. Host cell engineering has focused on preventing cell death, optimizing metabolic pathways, and improving glycosylation patterns, leading to enhanced productivity and product quality.

The integration of these emerging technologies has created new possibilities for process optimization and cost reduction. Machine learning applications, combined with advanced analytics, enable more precise process control and optimization than other technologies. Baako et al[39] have demonstrated that the application of various machine learning approaches, such as artificial neural networks, recurrent neural networks, and convolutional neural networks, has significantly improved process understanding and control in CHO cell bioprocessing.

Table 4 Impact of Manufacturing Approach on Product Quality

Quality Attribute	Batch	Fed-Batch	Continuous
Glycosylation consistency	High variability (±15-20%)	Moderate variability (±8-12%)	Low variability (±3-5%)
Charge variant profile	Variable basic variants	Controlled through pH	Highly consistent
High molecular weight species	Elevated levels (5–10%)	Moderate levels (2–5%)	Reduced levels (1–3%)
Host cell protein clearance	Challenging (150–300 ppm)	Moderate (50–150 ppm)	Improved (<50 ppm)

Looking forward, the convergence of these technologies presents both opportunities and challenges. While these advances offer the potential for significant improvements in manufacturing efficiency and product quality, they also require substantial investment in infrastructure and expertise. The successful implementation of these technologies demands careful consideration of:

- Integration with existing systems
- Personnel training requirements
- Regulatory compliance
- Cost–benefit analysis
- Scalability considerations

The future of mAb manufacturing lies in the successful integration of these emerging technologies, creating more efficient, flexible, and reliable production processes. As these technologies continue to evolve, their impact on manufacturing efficiency and product quality is expected to grow, potentially revolutionizing the biopharmaceutical manufacturing landscape.

Economic Analysis and Implementation in mAb Manufacturing

The economic analysis and implementation of mAb manufacturing processes require careful consideration of multiple factors, such as cost structures, risk assessment, and implementation strategies. Understanding these elements is crucial for successful process development and commercialization.

COG evaluation represents a fundamental aspect of economic analysis in mAb manufacturing. According to Farid et al,[4] process development and manufacturing costs constitute 13%–17% of the total R&D budget from pre-clinical to approval stages. Capital investment considerations must account for facility construction, equipment procurement, and infrastructure development. For a market to succeed with a 12% clinical success rate, companies typically require approximately 60 million USD for pre-clinical to Phase II material preparation and an additional 70 million USD for Phase III to regulatory review material preparation. Operational costs encompass raw materials, labor, utilities, and maintenance, with media costs often representing a significant portion of ongoing expenses. Scale-up economics demonstrate that production scale significantly influences cost-efficiency,[40] with continuous processing showing up to 35% cost savings for annual demand of 100–500 kg, though this advantage diminishes at larger scales.[8]

Risk assessment plays a crucial role in process implementation and economic evaluation. Process reliability concerns must address potential failure modes, system robustness, and contingency planning. Lim et al[41] indicate that perfusion,[42] while offering potential cost advantages, presents higher operational risks due to contamination and filter fouling issues than other processes. Quality considerations remain paramount, with emphasis on maintaining consistent product characteristics throughout the manufacturing process. Regulatory compliance requirements add another layer of complexity, necessitating careful documentation, validation, and ongoing monitoring to ensure adherence to current good manufacturing practice standards.

Implementation strategies require comprehensive planning and execution. Technology transfer represents a critical phase, demanding careful coordination between development and manufacturing teams. Research indicates that successful technology transfer requires:

- Detailed process characterization
- Clear documentation of critical process parameters
- Effective communication between sending and receiving sites
- Robust risk management strategies

Validation requirements must address equipment qualification, process validation, and cleaning validation. The implementation of new technologies or processes requires extensive validation studies to demonstrate consistent product quality and process control. Training needs require significant consideration, particularly when implementing advanced technologies, such as continuous processing or automated systems. Personnel must be adequately trained in:

- Standard operating procedures
- Equipment operation and maintenance
- Quality control methods
- Data analysis and interpretation
- Emergency response protocols

The successful implementation of mAb manufacturing processes depends on careful consideration of these economic and operational factors. Studies demonstrate that early consideration of implementation challenges during process development can significantly reduce technology transfer timelines and costs. Furthermore, the integration of risk assessment throughout the implementation process helps ensure successful outcomes while maintaining regulatory compliance.

This comprehensive approach to economic analysis and implementation provides a framework for successful mAb manufacturing process development and commercialization, while maintaining focus on cost-efficiency, risk management, and operational excellence.

Conclusions and Future Perspectives

The comprehensive analysis of mAb manufacturing reveals significant advances in process optimization, cost reduction strategies, and emerging technologies while highlighting critical areas for future development and research.

Key findings demonstrate a clear evolution in manufacturing approaches, with continuous processing showing substantial cost advantages of up to 35% for specific production scales.[8] The integration of single-use technologies and hybrid systems has enabled greater flexibility and reduced capital investment requirements, with hybrid facilities achieving break-even points 2–2.5 years earlier than traditional stainless steel facilities.[43] Additionally, advances in media optimization and process integration have led to significant improvements in production efficiency and cost reduction.

The implications for the biopharmaceutical industry are substantial. Manufacturers must carefully evaluate their production strategies based on scale-dependent considerations, with different approaches optimal at varying production volumes. The emergence of machine learning applications and advanced analytics has created new opportunities for process optimization and real-time control, though implementation requires significant investment in infrastructure and expertise. According to recent studies,[39] the integration of artificial intelligence and machine learning in bioprocess development has demonstrated remarkable potential in improving process understanding and control.

Future research directions should focus on several key areas:

1. Advanced Process Integration

- Development of more robust continuous processing platforms
- Improvement of real-time monitoring and control systems
- Integration of artificial intelligence in process optimization

2. Cost Reduction Strategies

- Novel media formulations and delivery systems
- Alternative purification technologies
- More efficient facility designs

3. Technology Development

- Enhanced cell line engineering approaches
- Improved vector design and expression systems
- Advanced analytical methods for process control

The field of mAb manufacturing continues to evolve rapidly, driven by technological advances and increasing demand for biological therapeutics. Success in this evolving landscape will require continued innovation in process design, optimization strategies, and implementation approaches. As highlighted by Nikolados and Oyarzún,[27,44] the integration of deep learning and other advanced technologies offers promising pathways for future developments in protein expression optimization and process control.

The future of mAb manufacturing lies in the successful integration of these elements, creating more efficient, flexible, and reliable production processes while maintaining product quality and regulatory compliance. Continued R&D in these areas will be crucial for meeting the growing global demand for mAb therapeutics while ensuring their economic viability and accessibility.

Acknowledgments

The discussion above reflects solely the personal views and considerations of the authors and does not constitute either legal advice or the views of the Pergament & Cepeda LLC. Thus, neither the authors nor Pergament & Cepeda can be bound either philosophically or as representatives of their various past, present, and future clients to the comments and views expressed herein. Although every attempt has been made to ensure that the statements herein are accurate, errors or omissions may be present for which we disclaim any liability.

Disclosure

The author reports no conflicts of interest in this work.

References

1. Singh SK, Nage N, Jagani H, Maiti M, Ranbhor RS. Glycan mapping of recombinant human follicle stimulating hormone by mass spectrometry. *Reprod Biol*. 2018;18(4):380–384. doi:10.1016/j.repbio.2018.10.003
2. Singh SK, Pokalwar S, Bose S, Gupta S, Almal S, Ranbhor RS. Structural and functional comparability study of anti-CD20 monoclonal antibody with reference product. *Biologics*. 2018;12:159–170. doi:10.2147/btt.S187744
3. Thennati R, Singh SK, Nage N, et al. Analytical characterization of recombinant hCG and comparative studies with reference product. *Biologics*. 2018;12:23–35. doi:10.2147/btt.S141203
4. Farid SS, Baron M, Stamatis C, Nie W, Coffman J. Benchmarking biopharmaceutical process development and manufacturing cost contributions to R&D. *MAbs*. 2020;12(1):1754999. doi:10.1080/19420862.2020.1754999
5. Zhang M, Hill T. Overcome challenges to successful manufacture of biosimilars through media and feed screening and cell culture process optimization. *J Bioanalysis Biomed*. 2016;08(02). doi:10.4172/1948-593x.1000148
6. Romero JJ, Jenkins EW, Osuofa J, Husson SM. Computational framework for the techno-economic analysis of monoclonal antibody capture chromatography platforms. *J Chromatogr A*. 2023;1689:463755. doi:10.1016/j.chroma.2022.463755
7. Bansode V, Gupta P, Kateja N, Rathore AS. Contribution of protein A step towards cost of goods for continuous production of monoclonal antibody therapeutics. *J Chem Technol Biotechnol*. 2021;97(9):2420–2433. doi:10.1002/jctb.6686
8. Mahal H, Branton H, Farid SS. End-to-end continuous bioprocessing: impact on facility design, cost of goods, and cost of development for monoclonal antibodies. *Biotechnol Bioeng*. 2021;118(9):3468–3485. doi:10.1002/bit.27774
9. Rathore AS, Kumar Singh S, Pathak M, et al. Fermentanomics: relating quality attributes of a monoclonal antibody to cell culture process variables and raw materials using multivariate data analysis. *Biotechnol Prog*. 2015;31(6):1586–1599. doi:10.1002/btpr.2155
10. Taiwo AE, Tom-James A, Musonge P. Economic assessment of cellulase production in batch and semi-batch solid-state fermentation processes. *Int J Low-Carbon Technol*. 2023;18:204–211. doi:10.1093/ijlct/ctad009
11. Matanguihan C, Wu P. Upstream continuous processing: recent advances in production of biopharmaceuticals and challenges in manufacturing. *Curr Opin Biotechnol*. 2022;78:102828. doi:10.1016/j.copbio.2022.102828
12. Mendes S, Gonçalves MCP, Aiex VAP, et al. Comparison between simple batch and fed-batch bioreactor cultivation of recombinant BCG. *Pharmaceutics*. 2024;16(11):1433. doi:10.3390/pharmaceutics16111433
13. Anand S, Srivastava P. Comparative study for the production of mycophenolic acid using penicillium brevicompactum in batch, fed- batch and continuous fermentation process. *Biointerf Res Appl Chem*. 2022;12:366–376. doi:10.33263/BRIAC121.366376
14. Yi AP. Principles and case studies of fed batch fermentation and continuous fermentation. *J Clin Nursing Res*. 2022;6(2):99–104. doi:10.26689/jcnr.v6i2.3712
15. Kelley B. The history and potential future of monoclonal antibody therapeutics development and manufacturing in four eras. *MAbs*. 2024;16(1):2373330. doi:10.1080/19420862.2024.2373330
16. Yang O, Qadan M, Ierapetritou M. Economic analysis of batch and continuous biopharmaceutical antibody production: a review. *J Pharm Innov*. 2019;14:1–19. doi:10.1007/s12247-018-09370-4
17. Pollard D, Brower M, Abe Y, Lopes AG, Sinclair A. Standardized economic cost modeling for next-generation mAb production. *Bioprocess Int*. 2016;14(8):14–23.
18. David L, Schwan P, Lobedann M, et al. Side-by-side comparability of batch and continuous downstream for the production of monoclonal antibodies. *Biotechnol Bioeng*. 2020;117(4):1024–1036. doi:10.1002/bit.27267
19. Botelho Ferreira K, Benlegrimet A, Diane G, et al. Transfer of continuous manufacturing process principles for mAb production in a GMP environment: a step in the transition from batch to continuous. *Biotechnol Progr*. 2022;38(4):e3259. doi:10.1002/btpr.3259

20. Cha HM, Hwang JM, Yeon JH, Lim JH, Han HJ, Kim DI. Commercial-scale economic comparison of different batch modes for upstream and downstream processing of monoclonal antibody. *Biotechnol Bioprocess Eng*. 2021;26:993–1001. doi:10.1007/s12257-020-0389-7
21. Klutz S, Holtmann L, Lobedann M, Schembecker G. Cost evaluation of antibody production processes in different operation modes. *Chem Eng Sci*. 2016;141:63–74. doi:10.1016/j.ces.2015.10.029
22. Kishishita S, Katayama S, Kodaira K, et al. Optimization of chemically defined feed media for monoclonal antibody production in Chinese hamster ovary cells. *J Biosci Bioeng*. 2015;120(1):78–84. doi:10.1016/j.jbiosc.2014.11.022
23. Pralong A, Levine HL, Lilja J, Gaasvik Å, Hummel H. Paradigm shift for vaccine manufacturing facilities: the next generation of flexible, modular facilities. *Eng Life Sci*. 2014;14(3):244–253. doi:10.1002/elsc.201400027
24. Peuker T, Bogner A. Equipment design and facility layout for flexible biomanufacturing processes. *Eng Life Sci*. 2011;11(4):443–451. doi:10.1002/elsc.201000174
25. Pinto J, Ramos JRC, Costa RS, Rossell S, Dumas P, Oliveira R. Hybrid deep modeling of a CHO-K1 fed-batch process: combining first-principles with deep neural networks. *Front Bioeng Biotechnol*. 2023;11:1237963. doi:10.3389/fbioe.2023.1237963
26. Mowbray M, Savage T, Wu C, et al. Machine learning for biochemical engineering: a review. *Biochem Eng J*. 2021;172:108054. doi:10.1016/j.bej.2021.108054
27. Nikolados EM, Oyarzun DA. Deep learning for optimization of protein expression. *Curr Opin Biotechnol*. 2023;81:102941. doi:10.1016/j.copbio.2023.102941
28. Worth RM, Espina L. ScanGrow: deep learning-based live tracking of bacterial growth in broth. *Front Microbiol*. 2022;13:900596. doi:10.3389/fmicb.2022.900596
29. Lu T, Jin M, Yang M, Huang D. Deep learning based prediction of critical parameters in CHO cell culture process and its application in monoclonal antibody production. *Int J Adv Applied Sci Res*. 2024;3:108–123.
30. Lakshmanan M, Chia S, Pang KT, et al. Antibody glycan quality predicted from CHO cell culture media markers and machine learning. *Comput Struct Biotechnol J*. 2024;23:2497–2506. doi:10.1016/j.csbj.2024.05.046
31. Melcher M, Scharl T, Spangl B, et al. The potential of random forest and neural networks for biomass and recombinant protein modeling in Escherichia coli fed-batch fermentations. *Biotechnol J*. 2015;10(11):1770–1782. doi:10.1002/biot.201400790
32. Wang G, Briskot T, Hahn T, et al. Root cause investigation of deviations in protein chromatography based on mechanistic models and artificial neural networks. *J Chromatogr A*. 2017;1515:146–153. doi:10.1016/j.chroma.2017.07.089
33. Agarwal H, Rathore AS, Hadpe SR, et al. Artificial neural network (ANN)-based prediction of depth filter loading capacity for filter sizing. *Biotechnol Prog*. 2016;32(6):1436–1443. doi:10.1002/btpr.2329
34. Hwangbo S, Sin G. Design of control framework based on deep reinforcement learning and Monte-Carlo sampling in downstream separation. *Comput Chem Eng*. 2020;140:106910. doi:10.1016/j.compchemeng.2020.106910
35. Nikita S, Tiwari A, Sonawat D, et al. Reinforcement learning based optimi- zation of process chromatography for continuous process- ing of biopharmaceuticals. *Chem Eng Sci*. 2021;230:116171. doi:10.1016/j.ces.2020.116171
36. Walsh I, Myint M, Nguyen-Khuong T, Ho YS, Ng SK, Lakshmanan M. Harnessing the potential of machine learning for advancing "Quality by Design" in biomanufacturing. *MAbs*. 2022;14(1):2013593. doi:10.1080/19420862.2021.2013593
37. Broly H, Costioli MD, Guillemot-Potelle C, Mitchell-Logean C. Cost of goods modeling and quality by design for developing cost-effective processes. *BioPharm Int*. 2010;23(6):1–12.
38. Majumdar S, Desai R, Hans A, Dandekar P, Jain R. From efficiency to yield: exploring recent advances in CHO cell line development for monoclonal antibodies. *mol Biotechnol*. 2024. doi:10.1007/s12033-024-01060-6
39. Baako T-MD, Kulkarni SK, McClendon JL, Harcum SW, Gilmore J. Machine learning and deep learning strategies for Chinese hamster ovary cell bioprocess optimization. *Fermentation*. 2024;10(5):234. doi:10.3390/fermentation10050234
40. Gupta P, Kateja N, Mishra S, Kaur H, Rathore AS. Economic assessment of continuous processing for manufacturing of biotherapeutics. *Biotechnol Prog*. 2021;37(2):e3108. doi:10.1002/btpr.3108
41. Lim AC, Washbrook J, Titchener-Hooker NJ, Farid SS. A computer-aided approach to compare the production economics of fed-batch and perfusion culture under uncertainty. *Biotechnol Bioeng*. 2006;93(4):687–697. doi:10.1002/bit.20757
42. Hashizume T, Ozawa Y, Ying BW. Employing active learning in the optimization of culture medium for mammalian cells. *NPJ Syst Biol Appl*. 2023;9(1):20. doi:10.1038/s41540-023-00284-7
43. Sinclair A, Monge M. Monoclonal antibody manufacturing: cost benefits of hybrid disposable systems. *Bioprocess Int*. 2011;9(9):12–17.
44. Nikolados EM, Wongprommoon A, Aodha OM, Cambray G, Oyarzun DA. Accuracy and data efficiency in deep learning models of protein expression. *Nat Commun*. 2022;13(1):7755. doi:10.1038/s41467-022-34902-5